Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Drug Resistance

  Free Subscription


Articles published in Int J Antimicrob Agents

Retrieve available abstracts of 237 articles:
HTML format



Single Articles


    March 2024
  1. HU J, Zha L, Yu YW, Su Q, et al
    Efficacy of Ceftazidime-Avibactam in the Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections: focus on Solid Organ Transplantation Recipients.
    Int J Antimicrob Agents. 2024 Mar 19:107152.
    PubMed     Abstract available


  2. HO LC, Yu Chi C, You YS, Hsieh YW, et al
    Impact of the implementation of the Intelligent Antimicrobial System (iAMS) on clinical outcomes among patients with bacteraemia caused by methicillin-resistant Staphylococcus aureus.
    Int J Antimicrob Agents. 2024 Mar 13:107142.
    PubMed     Abstract available


    February 2024
  3. KHARAT AS, Makwana N, Nasser M, Gayen S, et al
    Dramatic increase in antimicrobial resistance in ESKAPE clinical isolates over the 2010-2020 decade in India.
    Int J Antimicrob Agents. 2024 Feb 29:107125.
    PubMed     Abstract available


  4. WANG C, Bai C, Chen K, Du Q, et al
    International guidelines for the treatment of carbapenem-resistant Gram-negative bacilli infections: a comparison and evaluation.
    Int J Antimicrob Agents. 2024 Feb 26:107120.
    PubMed     Abstract available


  5. BOATTINI M, Bianco G, Llorente LI, Acero LA, et al
    Enterobacterales carrying chromosomal AmpC beta-lactamases in Europe (EuESCPM): epidemiology and antimicrobial resistance burden from a cohort of 27 hospitals, 2020-2022.
    Int J Antimicrob Agents. 2024 Feb 15:107115.
    PubMed     Abstract available


  6. YANG L, Gao Y, Zhang J, Tian C, et al
    Antimicrobial peptide DvAMP combats carbapenem-resistant Acinetobacter baumannii infection.
    Int J Antimicrob Agents. 2024 Feb 5:107106.
    PubMed     Abstract available


  7. WANG JL, Lai CC, Tsai YW, Ko WC, et al
    High ceftazidime-avibactam resistance among carbapenem-resistant Enterobacter species: Data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) programme, 2014-2021.
    Int J Antimicrob Agents. 2024 Feb 5:107105.
    PubMed     Abstract available


  8. SIVAY MV, Maksimenko LV, Nalimova TM, Nefedova AA, et al
    HIV drug resistance among patients experiencing antiretroviral therapy failure in Russia, 2019-2021.
    Int J Antimicrob Agents. 2024;63:107074.
    PubMed     Abstract available


  9. CHEN H, Hu P, Liu H, Liu S, et al
    Combining with domiphen bromide restores colistin efficacy against colistin-resistant Gram-negative bacteria in vitro and in vivo.
    Int J Antimicrob Agents. 2024;63:107066.
    PubMed     Abstract available


  10. WANG C, Zhang T, Wang Y, Wang Y, et al
    Proguanil and chlorhexidine augment the antibacterial activities of clarithromycin and rifampicin against Acinetobacter baumannii.
    Int J Antimicrob Agents. 2024;63:107065.
    PubMed     Abstract available


    January 2024
  11. FENG Y, Fang Q, Luo H, Li J, et al
    Safety and efficacy of a phage cocktail on murine wound infections caused by carbapenem-resistant Klebsiella pneumoniae.
    Int J Antimicrob Agents. 2024 Jan 11:107088.
    PubMed     Abstract available


  12. HSUEH CC, Lai CC, Tsai YW, Ko WC, et al
    Poor in vitro activity of ceftazidime/avibactam against carbapenem-resistant Escherichia coli and Klebsiella pneumoniae in India: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2018-2021.
    Int J Antimicrob Agents. 2024 Jan 11:107087.
    PubMed    


  13. HERSHKO Y, Rannon E, Adler A, Burstein D, et al
    WarA, a remote homolog of NpmA and KamB from Nocardia wallacei, confers broad spectrum aminoglycoside resistance in Nocardia and Mycobacteria.
    Int J Antimicrob Agents. 2024 Jan 11:107089.
    PubMed     Abstract available


  14. MUSHTAQ S, Vickers A, Woodford N, Livermore DM, et al
    Activity of aztreonam/avibactam and ceftazidime/avibactam against Enterobacterales with carbapenemase-independent carbapenem resistance.
    Int J Antimicrob Agents. 2024 Jan 2:107081.
    PubMed     Abstract available


  15. RATOUIT P, Malet I, Soulie C, Denis J, et al
    HIV-1 resistance mutations to integrase inhibitors impair both integration and reverse transcription steps.
    Int J Antimicrob Agents. 2024;63:107026.
    PubMed    


  16. PARK S, Choi J, Shin D, Kwon KT, et al
    Conversion to colistin susceptibility by tigecycline exposure in colistin-resistant Klebsiella pneumoniae and its implications to combination therapy.
    Int J Antimicrob Agents. 2024;63:107017.
    PubMed     Abstract available


  17. KIM SJ, Shin JH, Kim H, Ko KS, et al
    Roles of crrAB two-component regulatory system in Klebsiella pneumoniae: growth yield, survival in initial colistin treatment stage, and virulence.
    Int J Antimicrob Agents. 2024;63:107011.
    PubMed     Abstract available


    December 2023
  18. DU Y, Wang Y, Geng J, Long J, et al
    Molecular Mechanism of Hfq-dependent sRNA1039 and sRNA1600 Regulating Antibiotic Resistance and Virulence in Shigella sonnei.
    Int J Antimicrob Agents. 2023 Dec 21:107070.
    PubMed     Abstract available


  19. YU MC, Huang CK, Hung CS, Wang CH, et al
    Emerging insight of whole genome sequencing coupled with protein structure prediction into the pyrazinamide-resistance signature of Mycobacterium tuberculosis.
    Int J Antimicrob Agents. 2023 Dec 9:107053.
    PubMed     Abstract available


  20. KIAROSTAMI K, Fernandez-Barat L, Battaglini D, Motos A, et al
    The efficacy of telavancin in comparison with linezolid on endotracheal tube biofilm in pigs with methicillin-resistant Staphylococcus aureus pneumonia.
    Int J Antimicrob Agents. 2023 Dec 8:107052.
    PubMed     Abstract available


  21. JEON E, Kim MK, Park Y
    Efficacy of the bee-venom antimicrobial peptide Osmin against sensitive and carbapenem-resistant Klebsiella pneumoniae strains.
    Int J Antimicrob Agents. 2023 Dec 8:107054.
    PubMed     Abstract available


  22. GATTI M, Cosentino F, Giannella M, Viale P, et al
    Clinical efficacy of cefiderocol-based regimens in patients affected by carbapenem-resistant Acinetobacter baumannii infections: a systematic review with meta-analysis.
    Int J Antimicrob Agents. 2023 Dec 5:107047.
    PubMed     Abstract available


  23. HU T, Wang S, Bing J, Zheng Q, et al
    Hotspot mutations and genomic expansion of ERG11 are major mechanisms of azole resistance in environmental and human commensal isolates of Candida tropicalis.
    Int J Antimicrob Agents. 2023;62:107010.
    PubMed     Abstract available


    November 2023
  24. WANG SH, Yang KY, Sheu CC, Lin YC, et al
    Efficacy of combination therapy with standard-dose carbapenem for treating nosocomial pneumonia caused by carbapenem-resistant Acinetobacter baumannii in intensive care units: a multicenter retrospective propensity score-matched study.
    Int J Antimicrob Agents. 2023 Nov 29:107044.
    PubMed     Abstract available


  25. KUANG SF, Xiang J, Chen YT, Peng XX, et al
    Exogenous pyruvate promotes gentamicin uptake to kill antibiotic-resistant Vibrio alginolyticus.
    Int J Antimicrob Agents. 2023 Nov 17:107036.
    PubMed     Abstract available


  26. MUKHOPADHYAY S, Zhang P, To KKW, Liu Y, et al
    Sequential treatment effects on phage-antibiotic synergistic application against multi-drug-resistant Acinetobacter baumannii.
    Int J Antimicrob Agents. 2023;62:106951.
    PubMed     Abstract available


    October 2023
  27. XU C, Zeng F, Huang Y, Xu Q, et al
    Clinical Efficacy of Ceftazidime/avibactam Combination Therapy for Severe Hospital-acquired Pulmonary Infections Caused by Carbapenem-Resistant and Difficult-to-Treat Pseudomonas aeruginosa.
    Int J Antimicrob Agents. 2023 Oct 25:107021.
    PubMed     Abstract available


  28. CANTON R, Gottlieb T, Coombs GW, Woo PCY, et al
    Antimicrobial surveillance: a 20-year history of the SMART approach to addressing global antimicrobial resistance into the future.
    Int J Antimicrob Agents. 2023 Oct 20:107014.
    PubMed     Abstract available


  29. YU J, Lin HH, Tseng KH, Lin YT, et al
    Prediction of methicillin-resistant Staphylococcus aureus and carbapenem-resistant Klebsiella pneumoniae from flagged blood cultures by combining rapid Sepsityper MALDI-TOF mass spectra with machine learning.
    Int J Antimicrob Agents. 2023 Oct 4:106994.
    PubMed     Abstract available


  30. TAO H, Liu L, Chen X, Peng L, et al
    Coexistence of Klebsiella pneumoniae and Acinetobacter baumannii contributes to antibiotic resistance.
    Int J Antimicrob Agents. 2023 Oct 2:106993.
    PubMed    


  31. WANG Q, Peng K, Liu Z, Li Y, et al
    Genomic insights into linezolid-resistant Enterococci revealed its evolutionary diversity and poxtA copy number heterogeneity.
    Int J Antimicrob Agents. 2023;62:106929.
    PubMed     Abstract available


  32. GUILLAMET MCV, Damulira C, Atkinson A, Fraser VJ, et al
    Addition of aminoglycosides reduces recurrence of infections with multidrug-resistant Gram-negative bacilli in patients with sepsis and septic shock.
    Int J Antimicrob Agents. 2023;62:106913.
    PubMed     Abstract available


    September 2023
  33. CAI T, Novelli A, Tascini C, Stefani S, et al
    Rediscovering the value of fosfomycin trometamol in the era of antimicrobial resistance: a systematic review and expert opinion.
    Int J Antimicrob Agents. 2023 Sep 23:106983.
    PubMed     Abstract available


  34. LIU JY, Jia JJ, Liu M, Duan H, et al
    A novel indolylbenzoquinone compound HL-J6 suppresses biofilm formation and alpha-toxin secretion in methicillin-resistant Staphylococcus aureus.
    Int J Antimicrob Agents. 2023 Sep 21:106972.
    PubMed     Abstract available


  35. CAI T, Verze P, Arcaniolo D, Pandolfo SD, et al
    ANTIBIOTIC RESISTANCE PATTERNS AMONG UROPATHOGENS IN FEMALE OUTPATIENTS AFFECTED BY UNCOMPLICATED CYSTITIS: FOCUS ON FOSFOMYCIN TROMETAMOL.
    Int J Antimicrob Agents. 2023 Sep 20:106974.
    PubMed     Abstract available


  36. WU JW, Quyen TLT, Hsieh YC, Chen YY, et al
    Investigation of carbapenem-resistant Klebsiella pneumoniae in Taiwan revealed strains co-harboring bla(NDM) and bla(OXA-48-like) and a novel plasmid co-carrying bla(NDM-1) and bla(OXA-181).
    Int J Antimicrob Agents. 2023 Sep 4:106964.
    PubMed     Abstract available


  37. SALAMA EA, Eldesouky HE, Elgammal Y, Abutaleb NS, et al
    Lopinavir and ritonavir act synergistically with azoles against Candida auris in vitro and in a mouse model of disseminated candidiasis.
    Int J Antimicrob Agents. 2023;62:106906.
    PubMed     Abstract available


  38. ZHAO J, Zhu Y, Han ML, Lu J, et al
    Model-informed dose optimisation of polymyxin-rifampicin combination therapy against multidrug-resistant Acinetobacter baumannii.
    Int J Antimicrob Agents. 2023;62:106902.
    PubMed     Abstract available


  39. HAN Y, Zhang Y, Zeng W, Huang Z, et al
    Synergy with farnesol rejuvenates colistin activity against Colistin-resistant Gram-negative bacteria in vitro and in vivo.
    Int J Antimicrob Agents. 2023;62:106899.
    PubMed     Abstract available


  40. SHE Y, Jiang Y, Luo M, Duan X, et al
    Emergence of chromosomally located bla(CTX-M-14b) and qnrS1 in Salmonella enterica serotype Kentucky ST198 in China.
    Int J Antimicrob Agents. 2023;62:106896.
    PubMed     Abstract available


  41. WANG C, Tang B, Wu J, Jin X, et al
    Detection of mcr-1-harbouring Escherichia coli by quantum dot labelling of synthetic small peptides mimicking lipopolysaccharide receptors.
    Int J Antimicrob Agents. 2023;62:106898.
    PubMed     Abstract available


  42. ZHANG N, Shan W, Gao L, Kou SH, et al
    Repurposing the Hedgehog pathway inhibitor, BMS-833923, as a phosphatidylglycerol-selective membrane-disruptive colistin adjuvant against ESKAPE pathogens.
    Int J Antimicrob Agents. 2023;62:106888.
    PubMed     Abstract available


  43. AGYEMAN AA, Lopez-Causape C, Rogers KE, Lucas DD, et al
    Ceftolozane/tazobactam plus tobramycin against free-floating and biofilm bacteria of hypermutable Pseudomonas aeruginosa epidemic strains: Resistance mechanisms and synergistic activity.
    Int J Antimicrob Agents. 2023;62:106887.
    PubMed     Abstract available


    August 2023
  44. NISHIMURA B, Escalante J, Mezcord V, Tuttobene MR, et al
    HSA-induced modifications of Ton-B dependent receptors expression in cefiderocol-exposed carbapenem-resistant Acinetobacter baumannii (CRAB).
    Int J Antimicrob Agents. 2023 Aug 17:106950.
    PubMed    


  45. JONES DC, LaMartina EL, Lewis JR, Dahl AJ, et al
    One Health and Global Health View of Antimicrobial Susceptibility through the "Eye" of Aeromonas: Systematic Review and Meta-Analysis.
    Int J Antimicrob Agents. 2023;62:106848.
    PubMed     Abstract available


    July 2023
  46. MENG H, Yang J, Niu M, Zhu H, et al
    Risk factors and clinical outcomes of carbapenem-resistant Klebsiella pneumoniae bacteremia in children: a retrospective study.
    Int J Antimicrob Agents. 2023 Jul 25:106933.
    PubMed     Abstract available


  47. WU W, Wei S, Xue CX, Zhang W, et al
    An IncN-ST7 epidemic plasmid mediates the dissemination of carbapenem-resistant Klebsiella pneumoniae in a neonatal intensive care unit over 10 years, China.
    Int J Antimicrob Agents. 2023 Jul 9:106921.
    PubMed     Abstract available


  48. DANESHNIA F, Arastehfar A, Lombardi L, Binder U, et al
    Candida parapsilosis isolates carrying mutations outside FKS1 hotspot regions confer high echinocandin tolerance and facilitate the development of echinocandin resistance.
    Int J Antimicrob Agents. 2023;62:106831.
    PubMed     Abstract available


  49. YANG S, Peng X, Ren B, Luo Y, et al
    Small molecule II-6s synergises with fluconazole against Candida albicans.
    Int J Antimicrob Agents. 2023;62:106820.
    PubMed     Abstract available


    June 2023
  50. JIANG M, Li X, Xie CL, Chen P, et al
    Fructose enabled killing of antibiotic-resistant Salmonella Enteritidis by gentamicin: Insight from reprogramming metabolomics.
    Int J Antimicrob Agents. 2023 Jun 27:106907.
    PubMed     Abstract available


  51. CHOI MH, Kim D, Lee KH, Cho JH, et al
    Changes in the prevalence of hospital-acquired pneumonia-causing bacterial pathogens and the impact of their antimicrobial resistance patterns on clinical outcomes: A propensity score-matched study.
    Int J Antimicrob Agents. 2023 Jun 19:106886.
    PubMed     Abstract available


  52. SHENKUTIE AM, Gebrelibanos D, Yao M, Hundie GB, et al
    Impairment of novel non-coding small RNA00203 inhibits biofilm formation and reduces biofilm-specific antibiotic resistance in Acinetobacter baumannii.
    Int J Antimicrob Agents. 2023 Jun 12:106889.
    PubMed     Abstract available


  53. KOLLEF M, Dupont H, Greenberg DE, Viale P, et al
    The prospective role of cefiderocol in the management of carbapenem-resistant Acinetobacter baumannii infections: review of the evidence.
    Int J Antimicrob Agents. 2023 Jun 8:106882.
    PubMed     Abstract available


  54. QIAO L, Zuo W, Yang Y, Liu X, et al
    Clinical Outcomes and Safety of Intravenous Polymyxin B-based Treatment in Critically Ill Patients with Carbapenem-resistant Acinetobacter baumannii Nosocomial Pneumonia.
    Int J Antimicrob Agents. 2023 Jun 8:106880.
    PubMed     Abstract available


  55. CHEN CL, Janapatla RP, Dudek A, Chen YR, et al
    Functional characterization and clinical implication of a novel epidemic carbapenem-resistant Acinetobacter baumannii genetic marker.
    Int J Antimicrob Agents. 2023 Jun 6:106879.
    PubMed     Abstract available


  56. HU H, Shi Q, Zhang P, Quan J, et al
    Prevalence and molecular characteristics of colistin-resistant isolates among clinically isolated carbapenem-resistant Klebsiella pneumoniae in China.
    Int J Antimicrob Agents. 2023 Jun 3:106873.
    PubMed     Abstract available


    May 2023
  57. QU J, Xu J, Liu Y, Hu C, et al
    Real world effectiveness of ceftazidime/avibactam versus polymyxin B in treating patients with carbapenem-resistant Gram-negative bacterial infections.
    Int J Antimicrob Agents. 2023 May 27:106872.
    PubMed     Abstract available


  58. DING L, Guo Y, Hu F
    Antimicrobial Resistance Surveillance: China's nearly 40-Year Effort.
    Int J Antimicrob Agents. 2023 May 25:106869.
    PubMed    


  59. GATTI M, Rinaldi M, Tonetti T, Gaibani P, et al
    Pharmacokinetics/pharmacodynamics of cefiderocol administered by continuous infusion in a case series of critically ill patients with carbapenem-resistant Acinetobacter baumannii infections undergoing continuous venovenous haemodiafiltration (CVVHDF).
    Int J Antimicrob Agents. 2023 May 14:106852.
    PubMed     Abstract available


  60. GARCIA P, Moscoso M, Fernandez MC, Fuentes-Valverde V, et al
    Comparison of the in vivo efficacy of the ceftaroline fosamil, vancomycin and daptomycin in a murine model of methicillin-resistant Staphylococcus aureus bacteraemia.
    Int J Antimicrob Agents. 2023 May 5:106836.
    PubMed     Abstract available


  61. YANG Q, Zhu Y, Schwarz S, Wang L, et al
    Integrative and conjugative elements in streptococci can act as vectors for plasmids and translocatable units integrated via IS1216E.
    Int J Antimicrob Agents. 2023;61:106793.
    PubMed     Abstract available


  62. KARLOWSKY JA, Lob SH, Siddiqui F, Akrich B, et al
    In vitro activity of ceftolozane/tazobactam against multidrug-resistant Pseudomonas aeruginosa from patients in Western Europe: SMART 2017-2020.
    Int J Antimicrob Agents. 2023;61:106772.
    PubMed     Abstract available


  63. LAFFONT-LOZES P, Salipante F, Leguelinel-Blache G, Dunyach-Remy C, et al
    Effect of antimicrobial consumption on Escherichia coli resistance: assessment and forecasting using Dynamic Regression models in a French university hospital (2014-2019).
    Int J Antimicrob Agents. 2023;61:106768.
    PubMed     Abstract available


  64. JEAN SS, Liu IM, Hsieh PC, Kuo DH, et al
    Off-label use versus formal recommendations of conventional and novel antibiotics for the treatment of infections caused by multidrug-resistant bacteria.
    Int J Antimicrob Agents. 2023;61:106763.
    PubMed     Abstract available


    April 2023
  65. CAI J, Chen M, Liu Q, Luo J, et al
    Domination of an emerging erythromycin-resistant ptxP3 Bordetella pertussis clone in Shanghai, China.
    Int J Antimicrob Agents. 2023 Apr 29:106835.
    PubMed     Abstract available


  66. PLANKAOVA A, Brajerova M, Capek V, Novotna GB, et al
    Clostridioides difficile infections were predominantly driven by fluoroquinolone-resistant C. difficile ribotypes 176 and 001 in Slovakia in 2018-2019.
    Int J Antimicrob Agents. 2023 Apr 26:106824.
    PubMed     Abstract available


  67. RUSSO A, Bruni A, Gulli S, Borrazzo C, et al
    Efficacy of cefiderocol- versus colistin-containing regimen for treatment of bacteremic ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii in COVID-19 patients.
    Int J Antimicrob Agents. 2023 Apr 21:106825.
    PubMed     Abstract available


  68. HONDA H, Goto T, Uehara Y, Takamatsu A, et al
    Promotion of antimicrobial stewardship following the issuance of the antimicrobial resistance national action plan in Japan: a systematic review of 2016 to 2020.
    Int J Antimicrob Agents. 2023 Apr 21:106829.
    PubMed     Abstract available


  69. DE LA FUENTE C, Rodriguez M, Merino N, Carmona P, et al
    Real-life use of cefiderocol for salvage therapy of severe infections due to carbapenem-resistant Gram-negative bacteria.
    Int J Antimicrob Agents. 2023 Apr 14:106818.
    PubMed     Abstract available


  70. ZAKHOUR J, Haddad SF, Kerbage A, Heiman W, et al
    Diagnostic stewardship in infectious diseases: a continuum of antimicrobial stewardship in the fight against antimicrobial resistance.
    Int J Antimicrob Agents. 2023 Apr 13:106816.
    PubMed     Abstract available


  71. CHANG CY, Lee YL, Huang YT, Ko WC, et al
    In vitro activity of imipenem/relebactam, meropenem/vaborbactam and comparators against Enterobacterales causing urinary tract infection in Taiwan: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2020.
    Int J Antimicrob Agents. 2023 Apr 12:106815.
    PubMed     Abstract available


  72. TRECARICHI EM, Giuliano G, Cattaneo C, Ballanti S, et al
    Bloodstream infections due to Gram-negative bacteria in patients with hematologic malignancies: updated epidemiology and risk factors for multidrug-resistant strains in an Italian perspective survey.
    Int J Antimicrob Agents. 2023 Apr 6:106806.
    PubMed     Abstract available


  73. JO J, Park W, Kweon DH, Ko KS, et al
    Development mechanism of resistant population post-exposure to tigecycline in tigecycline-heteroresistant Acinetobacter baumannii strain.
    Int J Antimicrob Agents. 2023;61:106739.
    PubMed     Abstract available


  74. EINAV S, Leone M, Martin-Loeches I
    Sepsis and antibiotics: When should we deploy a parachute?
    Int J Antimicrob Agents. 2023;61:106732.
    PubMed     Abstract available


    March 2023
  75. YU J, Lin YT, Chen WC, Tseng KH, et al
    Direct prediction of carbapenem-resistant, carbapenemase-producing, and colistin-resistant Klebsiella pneumoniae isolates from routine MALDI-TOF mass spectra using machine learning and outcome evaluation.
    Int J Antimicrob Agents. 2023 Mar 31:106799.
    PubMed     Abstract available


  76. FORTUNATO G, Vaz-Moreira I, Gajic I, Manaia CM, et al
    Insight into phylogenomic bias of bla(VIM-2) or bla(NDM-1) dissemination amongst carbapenem resistant Pseudomonas aeruginosa.
    Int J Antimicrob Agents. 2023 Mar 14:106788.
    PubMed     Abstract available


  77. XIU L, Wang L, Li Y, Hu L, et al
    Multicentre Clinical Evaluation of a Molecular Diagnostic Assay to Identify Neisseria gonorrhoeae Infection and Detect Antimicrobial Resistance.
    Int J Antimicrob Agents. 2023 Mar 12:106785.
    PubMed     Abstract available


  78. ZHAO X, Li S, Zhang Y, Wang J, et al
    Ceftazidime-avibactam-based combination therapy for hospital-acquired central nervous system infections caused by carbapenem-resistant Klebsiella pneumoniae.
    Int J Antimicrob Agents. 2023 Mar 9:106777.
    PubMed     Abstract available


  79. SALADINI F, Giammarino F, Maggiolo F, Ferrara M, et al
    Residual phenotypic susceptibility to doravirine in multidrug-resistant HIV-1 from subjects enrolled in the PRESTIGIO Registry.
    Int J Antimicrob Agents. 2023;61:106737.
    PubMed     Abstract available


  80. HAGHANI I, Yahyazadeh Z, Hedayati MT, Shokohi T, et al
    Antifungal activity of miltefosine against both azole-susceptible and -resistant Aspergillus strains.
    Int J Antimicrob Agents. 2023;61:106715.
    PubMed     Abstract available


    February 2023
  81. CATTEAU L, Iglesias YD, Tsunemoto H, Pogliano J, et al
    Nafcillin Augmentation of Daptomycin and Cathelicidin LL-37 Killing of Methicillin-resistant Staphylococcus epidermidis: Foundations of Successful Therapy of Endocarditis.
    Int J Antimicrob Agents. 2023 Feb 10:106758.
    PubMed     Abstract available


  82. PU D, Zhao J, Lu B, Zhang Y, et al
    Within-host resistance evolution of a fatal ST11 hypervirulent carbapenem-resistant Klebsiella pneumoniae.
    Int J Antimicrob Agents. 2023 Feb 7:106747.
    PubMed     Abstract available


  83. CHEN CH, Wu PH, Lu MC, Ho MW, et al
    National surveillance of antimicrobial susceptibilities to ceftaroline, dalbavancin, telavancin, tedizolid, eravacycline, omadacycline, and other comparator antibiotics and genetic characteristics of bacteremic Staphylococcus aureus isolates in adults
    Int J Antimicrob Agents. 2023 Feb 7:106745.
    PubMed     Abstract available


  84. YU W, Zhang H, Zhu Y, Jia P, et al
    In vitro activity of ceftolozane/tazobactam against Pseudomonas aeruginosa collected in the Study for Monitoring Antimicrobial Resistance Trends (SMART) between 2016-2019 in China.
    Int J Antimicrob Agents. 2023 Feb 1:106741.
    PubMed     Abstract available


  85. KARRULI A, Massa A, Andini R, Marrazzo T, et al
    Clinical efficacy and safety of cefiderocol for resistant Gram-negative infections: a real-life, single-centre experience.
    Int J Antimicrob Agents. 2023;61:106723.
    PubMed     Abstract available


  86. HUMPHRIES RM, Janssen H, Hey-Hadavi JH, Hackel M, et al
    Multidrug-resistant Gram-negative bacilli recovered from respiratory and blood specimens from adults: the ATLAS surveillance program in European hospitals, 2018-2020.
    Int J Antimicrob Agents. 2023;61:106724.
    PubMed     Abstract available


    January 2023
  87. PATEL D, Brown ML, Edwards S, Oster RA, et al
    Outcomes of Daptomycin Plus Ceftaroline Versus Alternative Therapy for Persistent Methicillin-resistant Staphylococcus aureus (MRSA) Bacteremia.
    Int J Antimicrob Agents. 2023 Jan 20:106735.
    PubMed     Abstract available


  88. MALIN JJ, von Wintersdorff CJH, Penders J, Savelkoul PHM, et al
    Longitudinal fluctuations of common antimicrobial resistance genes in the gut microbiomes of healthy Dutch individuals.
    Int J Antimicrob Agents. 2023 Jan 11:106716.
    PubMed     Abstract available


  89. RHOUMA M, Madec JY, Laxminarayan R
    Colistin: From the shadows to a One Health approach for addressing antimicrobial resistance.
    Int J Antimicrob Agents. 2023 Jan 11:106713.
    PubMed     Abstract available


  90. CHEN CH, Wu PH, Lu MC, Ho MW, et al
    Geographic patterns of carbapenem-resistant, multidrug-resistant, and difficult-to-treat Acinetobacter baumannii in the Asia-Pacific Region: results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2020.
    Int J Antimicrob Agents. 2023 Jan 3:106707.
    PubMed     Abstract available


  91. NYAMANKOLLY E, Bellecave P, Wittkop L, Le Marec F, et al
    Long-term follow-up of HIV-1 multi-drug-resistant treatment-experienced participants treated with etravirine, raltegravir and boosted darunavir: towards drug-reduced regimen? ANRS CO3 Aquitaine Cohort 2007-2018.
    Int J Antimicrob Agents. 2023;61:106696.
    PubMed     Abstract available


    December 2022
  92. MEZCORD V, Wong O, Pasteran F, Corso A, et al
    Role of beta-lactamase inhibitors on cefiderocol activity against carbapenem-resistant Acinetobacter species.
    Int J Antimicrob Agents. 2022 Dec 2:106700.
    PubMed    


  93. GATTI M, Pascale R, Cojutti PG, Rinaldi M, et al
    A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime/avibactam in a case series of renal critically ill patients treated for documented carbapenem-resistant Gram-negative bloodstream infections and/or ventilator-as
    Int J Antimicrob Agents. 2022 Dec 1:106699.
    PubMed     Abstract available


    November 2022
  94. WOHLFARTH E, Kresken M, Higgins PG, Stefanik D, et al
    The evolution of carbapenem resistance determinants and major epidemiological lineages among carbapenem-resistant Acinetobacter baumannii isolates in Germany, 2010-2019.
    Int J Antimicrob Agents. 2022 Nov 11:106689.
    PubMed     Abstract available


  95. KAMUS L, Auger G, Gambarotto K, Houivet J, et al
    Investigation of a vanA linezolid- and vancomycin-resistant Enterococcus faecium outbreak in the Southwest Indian Ocean (Reunion Island).
    Int J Antimicrob Agents. 2022;60.
    PubMed     Abstract available


  96. GUENEAU R, Joannard B, Haddad N, Alby F, et al
    Extensive dermatophytosis caused by terbinafine-resistant Trichophyton indotineae, successfully treated with topical voriconazole.
    Int J Antimicrob Agents. 2022;60.
    PubMed    


  97. FAN F, Liu Y, Liu Y, Lv R, et al
    Candida albicans biofilms: antifungal resistance, immune evasion, and emerging therapeutic strategies.
    Int J Antimicrob Agents. 2022;60.
    PubMed     Abstract available


  98. GEUSAU A, Chromy D, Heissenberger D, Lippert K, et al
    Resistance profiles of Neisseria gonorrhoeae isolates in Vienna, Austria: a phenotypic and genetic characterization from 2013 to 2020.
    Int J Antimicrob Agents. 2022;60.
    PubMed     Abstract available


  99. WANG P, Liu D, Sun T, Zhang X, et al
    Pharmacokinetics and pharmacodynamics of polymyxin B and proposed dosing regimens in elderly patients with multi-drug-resistant Gram-negative bacterial infections.
    Int J Antimicrob Agents. 2022;60.
    PubMed     Abstract available


    October 2022
  100. HUANG YS, Sun HY, Chang SY, Chuang YC, et al
    Virological Responses to Tenofovir Alafenamide-Containing Antiretroviral Therapy in People Living with HIV Who Had Lamivudine-Resistant and Lamivudine-Susceptible Hepatitis B Virus Coinfection.
    Int J Antimicrob Agents. 2022 Oct 21:106682.
    PubMed     Abstract available


  101. TANG R, Luo R, Tang S, Song H, et al
    Machine learning in predicting antimicrobial resistance: a systematic review and meta-analysis.
    Int J Antimicrob Agents. 2022 Oct 21:106684.
    PubMed     Abstract available


  102. LEE YL, Ko WC, Hsueh PR
    Geographic patterns of global isolates of carbapenem-resistant Klebsiella pneumoniae and the activity of ceftazidime/avibactam, meropenem/vaborbactam, and comparators against these isolates: Results from the Antimicrobial Testing Leadership and Survei
    Int J Antimicrob Agents. 2022 Oct 11:106679.
    PubMed     Abstract available


  103. ANTONELLI A, Coppi M, Tellapragada C, Hasan B, et al
    Isothermal microcalorimetry vs checkerboard assay to evaluate in-vitro synergism of meropenem-amikacin and meropenem-colistin combinations against multi-drug-resistant Gram-negative pathogens.
    Int J Antimicrob Agents. 2022;60:106668.
    PubMed     Abstract available


  104. PHUADRAKSA T, Wichit S, Arikit S, Songtawee N, et al
    Co-occurrence of mcr-2 and mcr-3 genes on chromosome of multidrug-resistant Escherichia coli isolated from healthy individuals in Thailand.
    Int J Antimicrob Agents. 2022;60:106662.
    PubMed     Abstract available


  105. GYSIN M, Hon PY, Tan P, Sengduangphachanh A, et al
    Apramycin susceptibility of multidrug-resistant Gram-negative blood culture isolates in five countries in Southeast Asia.
    Int J Antimicrob Agents. 2022;60:106659.
    PubMed     Abstract available


  106. LAN P, Lu Y, Jiang Y, Wu X, et al
    Catecholate siderophore receptor CirA impacts cefiderocol susceptibility in Klebsiella pneumoniae.
    Int J Antimicrob Agents. 2022;60:106646.
    PubMed     Abstract available


  107. ZHOU H, Wang S, Wu Y, Dong N, et al
    Carriage of the mcr-9 and mcr-10 genes in clinical strains of the Enterobacter cloacae complex in China: a prevalence and molecular epidemiology study.
    Int J Antimicrob Agents. 2022;60:106645.
    PubMed     Abstract available


    September 2022
  108. LU Y, Liu JH, Yue C, Bergen PJ, et al
    Overexpression of mcr-1 disrupts cell envelope synthesis and causes the dysregulation of carbon metabolism, redox balance and nucleic acids.
    Int J Antimicrob Agents. 2022;60:106643.
    PubMed     Abstract available


  109. STELLA G, Volpicelli L, Carlo DD, Vicenti I, et al
    Impact of pre-existent drug resistance on virological efficacy of single-tablet regimens in people living with HIV.
    Int J Antimicrob Agents. 2022;60:106636.
    PubMed     Abstract available


  110. KANJ SS, Bassetti M, Kiratisin P, Rodrigues C, et al
    Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections.
    Int J Antimicrob Agents. 2022;60:106633.
    PubMed     Abstract available


    August 2022
  111. SIMITSOPOULOU M, Kadiltzoglou P, Antachopoulos C, Roilides E, et al
    Daptomycin exerts differential immunomodulatory effects on host responses against methicillin-resistant Staphylococcus aureus biofilms.
    Int J Antimicrob Agents. 2022 Aug 26:106666.
    PubMed     Abstract available


  112. HAJ CE, Benavent E, Sierra Y, Soldevila L, et al
    Comparative efficacy of dalbavancin alone and with rifampicin against in vitro biofilms in a pharmacodynamic model with methicillin-resistant Staphylococcus aureus.
    Int J Antimicrob Agents. 2022 Aug 21:106664.
    PubMed     Abstract available


  113. YEH TK, Lin HJ, Liu PY, Wang JH, et al
    Antibiotic resistance in Enterobacter hormaechei.
    Int J Antimicrob Agents. 2022 Aug 4:106650.
    PubMed     Abstract available


  114. WANG X, Wang Y, Jiang X, Gong X, et al
    Co-transfer of mcr-8 with blaNDM-1 or tmexCD1-toprJ1 by plasmid hybridisation.
    Int J Antimicrob Agents. 2022;60:106619.
    PubMed     Abstract available


  115. TISEO G, Brigante G, Giacobbe DR, Maraolo AE, et al
    Diagnosis and management of infections caused by multidrug-resistant bacteria: guideline endorsed by the Italian Society of Infection and Tropical Diseases (SIMIT), the Italian Society of Anti-Infective Therapy (SITA), the Italian Group for Antimicrob
    Int J Antimicrob Agents. 2022;60:106611.
    PubMed     Abstract available


  116. SACCO F, Raponi G, Oliva A, Bibbolino G, et al
    An outbreak sustained by ST15 Klebsiella pneumoniae carrying 16S rRNA methyltransferases and blaNDM: evaluation of the global dissemination of these resistance determinants.
    Int J Antimicrob Agents. 2022;60:106615.
    PubMed     Abstract available


    June 2022
  117. XIE M, Chen K, Chan EW, Zhang R, et al
    Characterization of clinical carbapenem-resistant K1 Klebsiella quasipneumoniae subsp. similipneumoniae strains harboring virulence plasmid.
    Int J Antimicrob Agents. 2022 Jun 24:106628.
    PubMed     Abstract available


  118. JUAN CH, Chou SH, Chen IR, Yang CI, et al
    Intestinal colonisation with hypervirulent or third-generation cephalosporin-resistant Klebsiella pneumoniae strains upon hospital admission in a general ward in Taiwan.
    Int J Antimicrob Agents. 2022 Jun 18:106624.
    PubMed     Abstract available


  119. JEAN SS, Lee YL, Hsu CW, Hsueh PR, et al
    In vitro susceptibilities of isolates of potentially naturally inducible chromosomal AmpC-producing metallo-beta-lactamase-negative carbapenem-resistant Enterobacterales species to ceftazidime-avibactam: Data from the Antimicrobial Testing Leadership
    Int J Antimicrob Agents. 2022 Jun 16:106617.
    PubMed     Abstract available


  120. BEMER P, Aubry A, Tessier E, d'Epenoux LR, et al
    Emergence of methicillin resistant Staphylococcus epidermidis resistant to linezolid: activity of ceftaroline versus ceftobiprole in a French University French Hospital.
    Int J Antimicrob Agents. 2022 Jun 9:106613.
    PubMed    


  121. ZHOU ZL, Tseng KY, Chen YZ, Tsai DJ, et al
    Genetic relatedness among azole-resistant Candida tropicalis clinical strains in Taiwan from 2014 to 2018.
    Int J Antimicrob Agents. 2022;59:106592.
    PubMed     Abstract available


  122. ELIAS R, Spadar A, Phelan J, Melo-Cristino J, et al
    A phylogenomic approach for the analysis of colistin resistance-associated genes in Klebsiella pneumoniae, its mutational diversity and implications for phenotypic resistance.
    Int J Antimicrob Agents. 2022;59:106581.
    PubMed     Abstract available


    May 2022
  123. KIM JH, Kim TS, Chang E, Kang CK, et al
    Effectiveness of antimicrobial stewardship programmes based on rapid antibiotic susceptibility testing of haematologic patients having high-risk factors for bacteraemia related mortality: A post-hoc analysis of an RCT.
    Int J Antimicrob Agents. 2022 May 16:106604.
    PubMed     Abstract available


  124. YU Y, Zhao H, Lin J, Li Z, et al
    Repurposing Non-Antibiotic Drugs Auranofin and Pentamidine in Combination to Combat Multidrug-Resistant Gram-Negative Bacteria.
    Int J Antimicrob Agents. 2022;59:106582.
    PubMed     Abstract available


  125. LIAO W, Cui Y, Quan J, Zhao D, et al
    High prevalence of colistin resistance and mcr-9/10 genes in Enterobacter spp. in a tertiary hospital over a decade.
    Int J Antimicrob Agents. 2022;59:106573.
    PubMed     Abstract available


    April 2022
  126. KOMEDA T, Shrestha S, Sherchan JB, Tohya M, et al
    Emergence of a highly colistin-resistant Aeromonas jandaei clinical isolate harbouring four genes encoding phosphoethanolamine transferases in Nepal.
    Int J Antimicrob Agents. 2022;59:106544.
    PubMed     Abstract available


    March 2022
  127. XU T, Zhou F, Wang L, Wu S, et al
    Metronidazole-Resistant Clostridioides difficile: Genomic and Transcriptomic Traits Acquired under In vitro Metronidazole Induction.
    Int J Antimicrob Agents. 2022 Mar 13:106570.
    PubMed     Abstract available


  128. JOZEFIKOVA A, Valcek A, Soltys K, Novakova E, et al
    Persistence and multi-ward dissemination of vancomycin resistant Enterococcus faecium ST17 clone in hospital settings in Slovakia from 2017 to 2020.
    Int J Antimicrob Agents. 2022 Mar 7:106561.
    PubMed     Abstract available


  129. BALANDIN B, Ballesteros D, Pintado V, Soriano-Cuesta C, et al
    Multicentre study of ceftazidime/avibactam for Gram-negative bacteria infections in critically ill patients.
    Int J Antimicrob Agents. 2022;59:106536.
    PubMed     Abstract available


  130. AHMADI A, Mohammadnejadi E, Karami P, Razzaghi-Asl N, et al
    Current Status and Structure Activity Relationship of Privileged Azoles as Antifungal Agents (2016-2020).
    Int J Antimicrob Agents. 2022;59:106518.
    PubMed     Abstract available


    February 2022
  131. ASLAN AT, Kirbas E, Sancak B, Tanriverdi ES, et al
    A retrospective observational cohort study of the clinical epidemiology of bloodstream infections due to carbapenem-resistant Klebsiella pneumoniae in an OXA-48 endemic setting.
    Int J Antimicrob Agents. 2022 Feb 14:106554.
    PubMed     Abstract available


  132. WANG J, Jiang Y, Ji RY, Wang ZY, et al
    Colistin- and tigecycline-resistant CTX-M-14-producing Salmonella enterica serovar Kentucky ST198 from retail chicken meat, China.
    Int J Antimicrob Agents. 2022;59:106504.
    PubMed    


  133. FONSECA EL, Morgado SM, Caldart RV, Freitas F, et al
    Emergence of a VIM-2-producing extensively drug-resistant (XDR) Pseudomonas aeruginosa ST309 in South America: a comparative genomic analysis.
    Int J Antimicrob Agents. 2022;59:106507.
    PubMed     Abstract available


  134. NANG SC, Li M, Harper M, Mandela E, et al
    Polymyxin causes cell envelope remodelling and stress responses in mcr-1-harbouring Escherichia coli.
    Int J Antimicrob Agents. 2022;59:106505.
    PubMed     Abstract available


  135. GUZMAN-PUCHE J, Perez-Nadales E, Perez-Vazquez M, Causse M, et al
    In vivo selection of KPC-94 and KPC-95 in Klebsiella pneumoniae isolates from patients treated with ceftazidime/avibactam.
    Int J Antimicrob Agents. 2022;59:106524.
    PubMed     Abstract available


    January 2022
  136. HUANG YC, Chen CJ
    USA 300 (sequence type 8) became a major clone of methicillin-resistant Staphylococcus aureus in northern Taiwan.
    Int J Antimicrob Agents. 2022 Jan 25:106534.
    PubMed     Abstract available


  137. DOBBYN D, Zeggil T, Kudrowich B, Beahm NP, et al
    Ciprofloxacin Resistances Rates in Escherichia coli Across Canada (CREAC): A Longitudinal Analysis 2015-2019.
    Int J Antimicrob Agents. 2022 Jan 25:106532.
    PubMed     Abstract available


  138. WANG WY, Hsueh PR, Tsao SM
    Genotyping of methicillin-resistant Staphylococcus aureus isolates causing invasive infections using spa typing and their correlation with antibiotic susceptibility.
    Int J Antimicrob Agents. 2022 Jan 15:106525.
    PubMed     Abstract available


  139. ARMENIA D, Santoro MM, Bellocchi MC, Carioti L, et al
    Viral resistance burden and APOBEC editing correlate with virological response in heavily treatment-experienced people living with multi-drug resistant HIV.
    Int J Antimicrob Agents. 2022;59:106492.
    PubMed     Abstract available


  140. PAN Y, Zeng Z, Niu H, Huang L, et al
    Whole-genome epidemiology and characterisation of mcr-1-encoding Escherichia coli in aquatic bird farms from the Pearl River Delta, China, 2019-2020.
    Int J Antimicrob Agents. 2022;59:106478.
    PubMed     Abstract available


  141. KAWAMOTO Y, Kaku N, Akamatsu N, Sakamoto K, et al
    The surveillance of colistin resistance and mobilized colistin resistance genes in multidrug-resistant Enterobacteriaceae isolated in Japan.
    Int J Antimicrob Agents. 2022;59:106480.
    PubMed     Abstract available


  142. YEH TK, Jean SS, Lee YL, Lu MC, et al
    Bacteriophages and phage-delivered CRISPR-Cas system as antibacterial therapy.
    Int J Antimicrob Agents. 2022;59:106475.
    PubMed     Abstract available


  143. LUO YC, Hsieh YC, Wu JW, Quyen TLT, et al
    Exploring the association between capsular types, sequence types, and carbapenemase genes in Acinetobacter baumannii.
    Int J Antimicrob Agents. 2022;59:106470.
    PubMed     Abstract available


  144. ARCA-SUAREZ J, Rodino-Janeiro BK, Perez A, Guijarro-Sanchez P, et al
    Emergence of 16S rRNA methyltransferases among carbapenemase-producing Enterobacterales in Spain studied by whole-genome sequencing.
    Int J Antimicrob Agents. 2022;59:106456.
    PubMed     Abstract available


    December 2021
  145. LEE SS, Cheng KF, Wong NS, Kwan CK, et al
    The emergence of antibiotic resistant Mycoplasma genitalium as the cause of non-gonococcal urethritis in male sexually transmitted infection clinic patients.
    Int J Antimicrob Agents. 2021 Dec 28:106510.
    PubMed     Abstract available


  146. WEI L, Feng Y, Wen H, Ya H, et al
    NDM-5-producing carbapenem-resistant Klebsiella pneumoniae of sequence type 789 emerged as a threat for neonates: a multi-center genome-based study.
    Int J Antimicrob Agents. 2021 Dec 24:106508.
    PubMed     Abstract available


  147. GARZA M, Mohan CV, Brunton L, Wieland B, et al
    Typology of interventions for antimicrobial use and antimicrobial resistance in aquaculture systems in LMICs.
    Int J Antimicrob Agents. 2021 Dec 9:106495.
    PubMed     Abstract available


  148. WESTERHOLT M, Hasman H, Hansen DS, Roer L, et al
    Screening patients at admission to Copenhagen hospitals for carriage of resistant bacteria after contact with healthcare systems abroad, 2016-2019.
    Int J Antimicrob Agents. 2021;58:106452.
    PubMed     Abstract available


  149. KIM JS, Yu JK, Jeon SJ, Park SH, et al
    Dissemination of an international high-risk clone of Escherichia coli ST410 co-producing NDM-5 and OXA-181 carbapenemases in Seoul, Republic of Korea.
    Int J Antimicrob Agents. 2021;58:106448.
    PubMed     Abstract available


  150. RECIO R, Viedma E, Gonzalez-Bodi S, Villa J, et al
    Clinical and bacterial characteristics of Pseudomonas aeruginosa affecting the outcome of patients with bacteraemic pneumonia.
    Int J Antimicrob Agents. 2021;58:106450.
    PubMed     Abstract available


  151. YOSHIKAWA Y, Feldhaus I, Ozcelik E, Hashiguchi TCO, et al
    Financial strategies targeting healthcare providers to promote the prudent use of antibiotics: a systematic review of the evidence.
    Int J Antimicrob Agents. 2021;58:106446.
    PubMed     Abstract available


    November 2021
  152. SEIFERT H, von Linstow ML, Janssen H, Dowzicky M, et al
    Antimicrobial Susceptibility among Gram-Negative Isolates in Pediatric Patients in Europe from 2013-2018 Compared to 2004-2012: Results from the ATLAS Surveillance Study.
    Int J Antimicrob Agents. 2021;58:106441.
    PubMed     Abstract available


  153. CEBRIAN R, Xu C, Xia Y, Wu W, et al
    The cathelicidin-derived close-to-nature peptide D-11 sensitises Klebsiella pneumoniae to a range of antibiotics in vitro, ex vivo and in vivo.
    Int J Antimicrob Agents. 2021;58:106434.
    PubMed     Abstract available


  154. ZHU C, Li C, Lai CKC, Ng R, et al
    Longitudinal Genomic Characterization of Carbapenemase-producing Enterobacteriaceae (CPE) Reveals Changing Pattern of CPE Isolated in Hong Kong Hospitals.
    Int J Antimicrob Agents. 2021;58:106430.
    PubMed     Abstract available


  155. GIUFRE M, Mazzolini E, Cerquetti M, Brusaferro S, et al
    Extended-spectrum beta-lactamase-producing Escherichia coli from extraintestinal infections in humans and from food-producing animals in Italy: a 'One Health' study.
    Int J Antimicrob Agents. 2021;58:106433.
    PubMed     Abstract available


  156. RODRIGUEZ-SANTIAGO J, Cornejo-Juarez P, Silva-Sanchez J, Garza-Ramos U, et al
    Polymyxin resistance in Enterobacterales: overview and epidemiology in the Americas.
    Int J Antimicrob Agents. 2021;58:106426.
    PubMed     Abstract available


  157. LENZI MH, Martins WM, Roch M, Ramos PL, et al
    A new mutation in mgrb mediating polymyxin resistance in Klebsiella variicola.
    Int J Antimicrob Agents. 2021;58:106424.
    PubMed     Abstract available


    October 2021
  158. BOAS DO PRADO GV, Mendes ET, Martins RCR, Perdigao-Neto LV, et al
    Phenotypic and genotypic characteristics of a Carbapenem-resistant Serratia marcescens cohort and outbreak: describing an opportunistic pathogen.
    Int J Antimicrob Agents. 2021 Oct 26:106463.
    PubMed     Abstract available


  159. UDE Z, Flothkotter N, Sheehan G, Brennan M, et al
    Multi-Targeted Metallo-Ciprofloxacin Derivatives Rationally Designed and Developed to Overcome Antimicrobial Resistance.
    Int J Antimicrob Agents. 2021 Oct 10:106449.
    PubMed     Abstract available


  160. CHEN T, Fu Y, Hua X, Xu Q, et al
    Acinetobacter baumannii strains isolated from cerebrospinal fluid (CSF) and bloodstream analysed by cgMLST: the dominance of clonal complex CC92 in CSF infections.
    Int J Antimicrob Agents. 2021;58:106404.
    PubMed     Abstract available


  161. MILTGEN G, Bour M, Allyn J, Allou N, et al
    Molecular and epidemiological investigation of a colistin-resistant OXA-23-/NDM-1-producing Acinetobacter baumannii outbreak in the Southwest Indian Ocean Area.
    Int J Antimicrob Agents. 2021;58:106402.
    PubMed     Abstract available


  162. SALVATO RS, Reis AJ, Schiefelbein SH, Gomez MAA, et al
    Genomic-based surveillance reveals high ongoing transmission of multi-drug-resistant Mycobacterium tuberculosis in Southern Brazil.
    Int J Antimicrob Agents. 2021;58:106401.
    PubMed     Abstract available


    September 2021
  163. MAGALLON J, Vu P, Reeves C, Kwan S, et al
    Amikacin in combination with zinc pyrithione prevents growth of a carbapenem-resistant/multidrug-resistant Klebsiella pneumoniae isolate.
    Int J Antimicrob Agents. 2021 Sep 19:106442.
    PubMed    


  164. CASTANHEIRA M, Doyle TB, Deshpande LM, Mendes RE, et al
    Activity of Ceftazidime-Avibactam, Meropenem-Vaborbactam, and Imipenem-Relebactam against Carbapenemase-negative Carbapenem-resistant Enterobacterales (CRE) isolates from US Hospitals.
    Int J Antimicrob Agents. 2021 Sep 18:106439.
    PubMed     Abstract available


  165. RUSSO A, Venditti M
    Vertebral osteomyelitis caused by vancomycin-resistant Enterococcus spp: a case series.
    Int J Antimicrob Agents. 2021 Sep 12:106432.
    PubMed    


  166. FOLETTO VS, da Rosa TF, Serafin MB, Bottega A, et al
    Repositioning of non-antibiotic drugs as an alternative to microbial resistance: a systematic review.
    Int J Antimicrob Agents. 2021;58:106380.
    PubMed     Abstract available


  167. MULDER M, Arp PP, Kiefte-de Jong JC, Uitterlinden AG, et al
    Prevalence of and risk factors for extended-spectrum beta-lactamase genes carriership in a population-based cohort of middle-aged and elderly.
    Int J Antimicrob Agents. 2021;58:106388.
    PubMed     Abstract available


  168. MORENO-MINGORANCE A, Espinal P, Rodriguez V, Goterris L, et al
    Circulation of multi-drug-resistant Shigella sonnei and Shigella flexneri among men who have sex with men in Barcelona, Spain, 2015-2019.
    Int J Antimicrob Agents. 2021;58:106378.
    PubMed     Abstract available


  169. FRATONI AJ, Kuti JL, Nicolau DP
    Optimised cefiderocol exposures in a successfully treated critically ill patient with polymicrobial Stenotrophomonas maltophilia bacteraemia and pneumonia receiving continuous venovenous haemodiafiltration.
    Int J Antimicrob Agents. 2021;58:106395.
    PubMed    


  170. FUENTES-CASTILLO D, Shiva C, Lincopan N, Sano E, et al
    Global high-risk clone of extended-spectrum beta-lactamase (ESBL)-producing Klebsiella pneumoniae ST307 emerging in livestock in Peru.
    Int J Antimicrob Agents. 2021;58:106389.
    PubMed    


    August 2021
  171. KIM JS, Yu JK, Jeon SJ, Park SH, et al
    Distribution of mcr genes among carbapenem-resistant Enterobacterales clinical isolates: High prevalence of mcr-positive Enterobacter cloacae complex in Seoul, Republic of Korea.
    Int J Antimicrob Agents. 2021 Aug 12:106418.
    PubMed     Abstract available


  172. ALLEN GP, Deao KM, Hill SA, Schipelliti SM, et al
    In vitro evaluation of antimicrobial resistance selection in Neisseria gonorrhoeae.
    Int J Antimicrob Agents. 2021 Aug 12:106417.
    PubMed     Abstract available


  173. IWU CD, Patrick SM
    An insight into the Implementation of the Global Action Plan on Antimicrobial Resistance in the WHO African Region: A Roadmap for Action.
    Int J Antimicrob Agents. 2021 Aug 6:106411.
    PubMed     Abstract available


  174. LU S, Li D, Wang L, Bi Y, et al
    Promoter variations associated with expression of mcr-1 gene and level of colistin resistance.
    Int J Antimicrob Agents. 2021;58:106371.
    PubMed     Abstract available


  175. LI J, Roberts J
    Antibiotic pharmacokinetics/pharmacodynamics: where are we heading?
    Int J Antimicrob Agents. 2021;58:106369.
    PubMed    


  176. JUNCO SJ, Bowman MC, Turner RB
    Clinical outcomes of Stenotrophomonas maltophilia infection treated with trimethoprim/sulfamethoxazole, minocycline, or fluoroquinolone monotherapy.
    Int J Antimicrob Agents. 2021;58:106367.
    PubMed     Abstract available


  177. RAO GG, Landersdorfer CB
    Antibiotic pharmacokinetic/pharmacodynamic modelling: MIC, pharmacodynamic indices and beyond.
    Int J Antimicrob Agents. 2021;58:106368.
    PubMed     Abstract available


    July 2021
  178. WARETH G, Linde J, Hammer P, Nguyen NH, et al
    Corrigendum to "Phenotypic and WGS-derived antimicrobial resistance profiles of clinical and non-clinical Acinetobacter baumannii isolates from Germany and Vietnam" [International Journal of Antimicrobial Agents, Volume 56, Issue 4, October 2020, 1061
    Int J Antimicrob Agents. 2021 Jul 26:106407.
    PubMed    


  179. RAMBLIERE L, Guillemot D, Delarocque-Astagneau E, Huynh BT, et al
    Erratum to "Impact of mass and systematic antibiotic administration on antibiotic resistance in low- and middle-income countries. A systematic review" [International Journal of Antimicrobial Agents (2021) Volume 58, Issue 1/106364].
    Int J Antimicrob Agents. 2021 Jul 14:106396.
    PubMed    


  180. ANTONELLO RM, Di Bella S, Betts J, La Ragione R, et al
    Zidovudine in synergistic combination with fosfomycin: an in vitro and in vivo evaluation against multidrug-resistant Enterobacterales.
    Int J Antimicrob Agents. 2021;58:106362.
    PubMed     Abstract available


  181. LAI CC, Yu WL
    Klebsiella pneumoniae Harboring Carbapenemase Genes in Taiwan: Its Evolution over 20 Years, 1998-2019.
    Int J Antimicrob Agents. 2021;58:106354.
    PubMed     Abstract available


    June 2021
  182. LEE YL, Ko WC, Lee WS, Lu PL, et al
    In vitro activity of cefiderocol, cefepime/zidebactam, cefepime/enmetazobactam, omadacycline, eravacycline, and other comparative agents against carbapenem-nonsusceptible Enterobacterales: Results from the Surveillance of Multicenter Antimicrobial Res
    Int J Antimicrob Agents. 2021 Jun 21:106377.
    PubMed     Abstract available


  183. CHAIYACHAT P, Chaiprasert A, Nonghanphithak D, Smithtikarn S, et al
    Whole-genome analysis of drug-resistant Mycobacterium tuberculosis reveals novel mutations associated with fluoroquinolone resistance.
    Int J Antimicrob Agents. 2021 Jun 20:106385.
    PubMed     Abstract available


  184. MOOR J, Aebi S, Rickli S, Mostacci N, et al
    Dynamics of extended-spectrum cephalosporin-resistant E. coli in pig farms: A longitudinal study.
    Int J Antimicrob Agents. 2021 Jun 19:106382.
    PubMed     Abstract available


  185. TIMMERMANS M, Wattiau P, Denis O, Boland C, et al
    Colistin resistance genes mcr-1 to mcr-5, including a case of triple occurrence (mcr-1, -3 and -5), in Escherichia coli isolates from faeces of healthy pigs, cattle and poultry in Belgium, 2012-2016.
    Int J Antimicrob Agents. 2021;57:106350.
    PubMed     Abstract available


  186. CLERICI D, Oltolini C, Greco R, Ripa M, et al
    The place of ceftazidime/avibactam and ceftolozane/tazobactam for therapy of haematological patients with febrile neutropenia.
    Int J Antimicrob Agents. 2021;57:106335.
    PubMed     Abstract available


  187. ALMANGOUR TA, Garcia E, Zhou Q, Forrest A, et al
    Polymyxins for the treatment of lower respiratory tract infections: lessons learned from the integration of clinical pharmacokinetic studies and clinical outcomes.
    Int J Antimicrob Agents. 2021;57:106328.
    PubMed     Abstract available


    May 2021
  188. RAMBLIERE L, Guillemot D, Delarocque-Astagneau E, Huynh BT, et al
    What is the impact of mass and systematic antibiotic administration on antibiotic resistance in low- and middle-income countries? A systematic review: AR after mass/systematic antibiotic administration.
    Int J Antimicrob Agents. 2021 May 24:106364.
    PubMed     Abstract available


  189. DELORY T, Gravier S, Pluart DL, Gaube G, et al
    Temocillin versus carbapenems for urinary tract infection due to ESBL-producing Enterobacteriaceae: a multicenter matched case-control study.
    Int J Antimicrob Agents. 2021 May 14:106361.
    PubMed     Abstract available


  190. TSAI HY, Lee YL, Liu PY, Lu MC, et al
    Antimicrobial susceptibility of bacteremic vancomycin-resistant Enterococcus faecium to eravacycline, omadacycline, lipoglycopeptides, and other comparator antibiotics: Results from the 2019/2020 Nationwide Surveillance of Multicenter Antimicrobial Re
    Int J Antimicrob Agents. 2021 May 4:106353.
    PubMed     Abstract available


  191. MEI CY, Wu H, Wang Y, Wang ZY, et al
    First detection of the multiresistance gene cfr in Escherichia coli from retail vegetables, China.
    Int J Antimicrob Agents. 2021;57:106348.
    PubMed    


  192. MBHELE N, Chimukangara B, Gordon M
    HIV-1 integrase strand transfer inhibitors: a review of current drugs, recent advances and drug resistance.
    Int J Antimicrob Agents. 2021;57:106343.
    PubMed     Abstract available


  193. WANG X, Ling Z, Sun N, Liu Y, et al
    Molecular genetic characteristics of mcr-9-harbouring Salmonella enterica serotype Typhimurium isolated from raw milk.
    Int J Antimicrob Agents. 2021;57:106332.
    PubMed     Abstract available


  194. NGUYEN HT, Venter H, Veltman T, Williams R, et al
    In vitro synergistic activity of NCL195 in combination with colistin against Gram-negative bacterial pathogens.
    Int J Antimicrob Agents. 2021;57:106323.
    PubMed     Abstract available


  195. MUSHTAQ S, Garello P, Vickers A, Woodford N, et al
    Cefepime/tazobactam compared with other tazobactam combinations against problem Gram-negative bacteria.
    Int J Antimicrob Agents. 2021;57:106318.
    PubMed     Abstract available


    April 2021
  196. KOSTYANEV T, Xavier BB, Garcia-Castillo M, Lammens C, et al
    Phenotypic and Molecular Characterisations of Carbapenem-resistant Acinetobacter baumannii Isolates Collected within the EURECA Study.
    Int J Antimicrob Agents. 2021 Apr 19:106345.
    PubMed     Abstract available


  197. HUANG PH, Cheng YH, Chen WY, Juan CH, et al
    Risk factors and mechanisms of in vivo emergence of colistin resistance in carbapenem-resistant Klebsiella pneumoniae.
    Int J Antimicrob Agents. 2021 Apr 14:106342.
    PubMed     Abstract available


  198. CREMET L, Leroy AG, Muller D, Delanou S, et al
    Antibiotic Resistance Heterogeneity and LasR Diversity within Pseudomonas aeruginosa Populations from Pneumonia in Intensive Care Unit Patients.
    Int J Antimicrob Agents. 2021 Apr 12:106341.
    PubMed     Abstract available


  199. SCUDELLER L, Righi E, Chiamenti M, Bragantini D, et al
    Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli.
    Int J Antimicrob Agents. 2021 Apr 12:106344.
    PubMed     Abstract available


  200. TANG SSL, Chee E, Teo JQ, Chlebicki MP, et al
    Incidence of a subsequent carbapenem-resistant Enterobacteriaceae infection after previous colonisation or infection: a prospective cohort study.
    Int J Antimicrob Agents. 2021 Apr 12:106340.
    PubMed     Abstract available


  201. KLEIN S, Boutin S, Heeg K, Zanger P, et al
    Genomic structure of ST8-t008 USA300 and USA300-LV MRSA in the Rhine-Neckar Region, Germany, 2012-2018.
    Int J Antimicrob Agents. 2021;57:106312.
    PubMed     Abstract available


  202. HERRERA M, Gregorio SD, Haim MS, Posse G, et al
    Genetic changes associated with tigecycline resistance in Staphylococcus aureus in vitro-selected mutants belonging to different lineages.
    Int J Antimicrob Agents. 2021;57:106304.
    PubMed     Abstract available


    March 2021
  203. BONNIN RA, Girlich D, Jousset AB, Emeraud C, et al
    Genomic analysis of VIM-2-producing Enterobacter hormaechei subsp. steigerwaltii.
    Int J Antimicrob Agents. 2021;57:106285.
    PubMed     Abstract available


  204. NI M, Zhao L, Zhang WJ, Ma JW, et al
    Pharmacokinetics of colistin in cerebrospinal fluid after intraventricular administration alone in intracranial infections.
    Int J Antimicrob Agents. 2021;57:106281.
    PubMed     Abstract available


  205. JOHNSON MG, Bruno C, Castanheira M, Yu B, et al
    Evaluating the emergence of nonsusceptibility among Pseudomonas aeruginosa respiratory isolates from a phase-3 clinical trial for treatment of nosocomial pneumonia (ASPECT-NP).
    Int J Antimicrob Agents. 2021;57:106278.
    PubMed     Abstract available


  206. VAN BILSEN WPH, van Dulm E, Matser A, Linde I, et al
    High carriage of ESBL-producing Enterobacteriaceae associated with sexual activity among men who have sex with men.
    Int J Antimicrob Agents. 2021;57:106276.
    PubMed     Abstract available


  207. BALANDIN B, Ballesteros D, Ruiz de Luna R, Lopez-Vergara L, et al
    Multicenter study of ceftolozane/tazobactam for treatment of Pseudomonas aeruginosa infections in critically ill patients.
    Int J Antimicrob Agents. 2021;57:106270.
    PubMed     Abstract available


  208. CIMOLAI N
    Pharmacotherapy for Bordetella pertussis infection. II. A synthesis of clinical sciences.
    Int J Antimicrob Agents. 2021;57:106257.
    PubMed     Abstract available


  209. CIMOLAI N
    Pharmacotherapy for Bordetella pertussis infection. I. A synthesis of laboratory sciences.
    Int J Antimicrob Agents. 2021;57:106258.
    PubMed     Abstract available


    February 2021
  210. HERNANDEZ-GARCIA M, Garcia-Fernandez S, Garcia-Castillo M, Melo-Cristino J, et al
    Confronting Ceftolozane-Tazobactam Susceptibility in Multidrug-Resistant Enterobacterales Isolates and Whole-Genome Sequencing Results (STEP Study).
    Int J Antimicrob Agents. 2021;57:106259.
    PubMed     Abstract available


  211. CHERNOVA OA, Chernov VM, Mouzykantov AA, Baranova NB, et al
    Antimicrobial drug resistance mechanisms among Mollicutes.
    Int J Antimicrob Agents. 2021;57:106253.
    PubMed     Abstract available


  212. XU Q, Sheng Z, Hao M, Jiang J, et al
    RamA upregulates multidrug resistance efflux pumps AcrAB and OqxAB in Klebsiella pneumoniae.
    Int J Antimicrob Agents. 2021;57:106251.
    PubMed     Abstract available


  213. LOMBARDI F, Giacomelli A, Armenia D, Lai A, et al
    Prevalence and factors associated with HIV-1 multi-drug resistance over the past two decades in the Italian ARCA database.
    Int J Antimicrob Agents. 2021;57:106252.
    PubMed     Abstract available


  214. GOMEZ-JUNYENT J, Murillo O, Yu HH, Azad MAK, et al
    In vitro pharmacokinetics/pharmacodynamics of continuous ceftazidime infusion alone and in combination with colistin against Pseudomonas aeruginosa biofilm.
    Int J Antimicrob Agents. 2021;57:106246.
    PubMed     Abstract available


    January 2021
  215. PICCIRILLI A, Segatore B, Brisdelli F, Amicosante G, et al
    Potent inhibitory activity of taniborbactam towards NDM-1 and NDM-1(Q119X) mutants, and in vitro activity of cefepime/taniborbactam against MBLs producing Enterobacterales.
    Int J Antimicrob Agents. 2021;57:106228.
    PubMed     Abstract available


  216. HUANG L, Cao M, Hu Y, Zhang R, et al
    Prevalence and mechanisms of fosfomycin resistance among KPC-producing Klebsiella pneumoniae clinical isolates in China.
    Int J Antimicrob Agents. 2021;57:106226.
    PubMed     Abstract available


  217. FREITAS AR, Pereira AP, Novais C, Peixe L, et al
    Multidrug-resistant high-risk Enterococcus faecium clones: can we really define them?
    Int J Antimicrob Agents. 2021;57:106227.
    PubMed     Abstract available


  218. OUCHAR MAHAMAT O, Kempf M, Lounnas M, Tidjani A, et al
    Epidemiology and prevalence of extended-spectrum beta-lactamase- and carbapenemase-producing Enterobacteriaceae in humans, animals and the environment in West and Central Africa.
    Int J Antimicrob Agents. 2021;57:106203.
    PubMed     Abstract available


    August 2020
  219. IANNACCONE M, Boattini M, Bianco G, Cavallo R, et al
    Meropenem/vaborbactam-based combinations against KPC-producing Klebsiella pneumoniae and multidrug-resistant Pseudomonas aeruginosa.
    Int J Antimicrob Agents. 2020;56:106066.
    PubMed    


  220. ANDRE-GARNIER E, Hingrat QL, Marcelin AG, Reliquet V, et al
    Previously unreported emergence of A265V substitution in the integrase gene in association with bictegravir virological failure.
    Int J Antimicrob Agents. 2020;56:106039.
    PubMed    


    July 2020
  221. MOWLABOCCUS S, Daley D, Pang S, Gottlieb T, et al
    Identification and Characterisation of Fosfomycin Resistance in Escherichia coli Urinary Tract Infection Isolates from Australia.
    Int J Antimicrob Agents. 2020 Jul 30:106121.
    PubMed     Abstract available


  222. NGUYEN HM, Graber CJ
    A Critical Review of Cephalexin and Cefadroxil for the Treatment of Acute Uncomplicated Lower Urinary Tract Infection in the Era of "Bad Bugs, Few Drugs".
    Int J Antimicrob Agents. 2020 Jul 10:106085.
    PubMed     Abstract available


  223. MARTINS WMBS, Seco BMS, Sampaio JLM, Sands K, et al
    Detection of BKC-1 in Citrobacter freundii: A clue to mobilisation in an IncQ1 plasmid carrying blaBKC-1.
    Int J Antimicrob Agents. 2020;56:106042.
    PubMed    


  224. HSU CY, Chen FJ, Huang WC, Liao YC, et al
    Plasmid- and chromosome-located mcr-3 in mcr-1-positive Escherichia coli in Taiwan.
    Int J Antimicrob Agents. 2020;56:105996.
    PubMed    


  225. FURLAN JPR, Savazzi EA, Stehling EG
    Widespread high-risk clones of multidrug-resistant extended-spectrum beta-lactamase-producing Escherichia coli B2-ST131 and F-ST648 in public aquatic environments.
    Int J Antimicrob Agents. 2020;56:106040.
    PubMed     Abstract available


  226. PEREZ-VAZQUEZ M, Sola-Campoy PJ, Zurita AM, Avila A, et al
    Carbapenemase-producing Pseudomonas aeruginosa in Spain: interregional dissemination of the high-risk clones ST175 and ST244 carrying blaVIM-2, blaVIM-1, blaIMP-8, blaVIM-20 and blaKPC-2.
    Int J Antimicrob Agents. 2020;56:106026.
    PubMed     Abstract available


  227. SANTORO MM, Fornabaio C, Malena M, Galli L, et al
    Susceptibility to HIV-1 integrase strand transfer inhibitors (INSTIs) in highly treatment-experienced patients who failed an INSTI-based regimen.
    Int J Antimicrob Agents. 2020;56:106027.
    PubMed     Abstract available


  228. GAURAV A, Kothari A, Omar BJ, Pathania R, et al
    Assessment of polymyxin B-doxycycline in combination against Pseudomonas aeruginosa in vitro and in a mouse model of acute pneumonia.
    Int J Antimicrob Agents. 2020;56:106022.
    PubMed     Abstract available


  229. BARBOSA F, Pinto E, Kijjoa A, Pinto M, et al
    Targeting antimicrobial drug resistance with marine natural products.
    Int J Antimicrob Agents. 2020;56:106005.
    PubMed     Abstract available


  230. WILLCOCKS SJ, Cia F, Francisco AF, Wren BW, et al
    Revisiting aminocoumarins for the treatment of melioidosis.
    Int J Antimicrob Agents. 2020;56:106002.
    PubMed     Abstract available


  231. CHEN L, Han D, Tang Z, Hao J, et al
    Co-existence of the oxazolidinone resistance genes cfr and optrA on two transferable multi-resistance plasmids in one Enterococcus faecalis isolate from swine.
    Int J Antimicrob Agents. 2020;56:105993.
    PubMed     Abstract available


  232. KAVANAUGH LG, Flanagan JN, Steck TR
    Reciprocal antibiotic collateral sensitivity in Burkholderia multivorans.
    Int J Antimicrob Agents. 2020;56:105994.
    PubMed     Abstract available


  233. DOGAN O, Yesilkaya A, Menekse S, Guler O, et al
    Effect of initial antifungal therapy on mortality among patients with bloodstream infections with different Candida species and resistance to antifungal agents: A multicentre observational study by the Turkish Fungal Infections Study Group.
    Int J Antimicrob Agents. 2020;56:105992.
    PubMed     Abstract available


  234. NOEL A, Attwood M, Bowker K, MacGowan A, et al
    The pharmacodynamics of fosfomycin against Staphylococcus aureus studied in an in vitro model of infection.
    Int J Antimicrob Agents. 2020;56:105985.
    PubMed     Abstract available


  235. STRAZZULLA A, Iordache L, de Pontfarcy A, Pitsch A, et al
    beta-Lactam allergy and risk of multidrug-resistant bacteria in the intensive care unit: A cohort study.
    Int J Antimicrob Agents. 2020;56:105979.
    PubMed     Abstract available


  236. CAI T, Tamanini I, Mattevi D, Verze P, et al
    Fosfomycin trometamol and N-acetyl-L-cysteine as combined oral therapy of difficult-to-treat chronic bacterial prostatitis: Results of a pilot study.
    Int J Antimicrob Agents. 2020;56:105935.
    PubMed     Abstract available


  237. PERALES C
    Quasispecies dynamics and clinical significance of hepatitis C virus (HCV) antiviral resistance.
    Int J Antimicrob Agents. 2020;56:105562.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Drug Resistance is free of charge.